TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

TrustFinance Global Insights
Thg 05 06, 2026
2 min read
19

J.P. Morgan has maintained its "underweight" rating for the chemical company Wacker Chemie (ETR:WCHG). The investment bank also updated its long-term price target for the company's stock, signaling a continued cautious stance.
In a note released on Wednesday, J.P. Morgan analysts confirmed the "underweight" recommendation. Concurrently, they increased the December 2027 price target for Wacker Chemie to €60, a revision from the previous target of €50.
The new price target of €60 represents a potential downside of approximately 37 percent when compared to the stock’s last closing price of €95.30. This significant gap suggests a bearish outlook from the analyst despite the upward revision of the price target.
Investors will be observing the market's reaction to this updated analyst perspective. The key takeaway is the sustained negative rating, which overshadows the modest increase in the long-term valuation target, indicating potential headwinds for the stock.
Q: What was J.P. Morgan's new rating for Wacker Chemie?
A: J.P. Morgan maintained its existing "underweight" rating; it did not issue a new one.
Q: What is the new price target for Wacker Chemie?
A: The new December 2027 price target is €60, raised from the previous target of €50.
Source: Investing.com

TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Related Articles

09 Thg 05 2026
Insurance Firm Safepoint Seeks IPO Amid Profit Surge

09 Thg 05 2026
US: Taiwan Defense Budget Delays a 'Concession' to China

08 Thg 05 2026
Russia Scales Back Victory Day Amid Ukraine War

08 Thg 05 2026
Moderna Stock Soars on Hantavirus Vaccine Plans

08 Thg 05 2026
Applied Aerospace & Defense Files for IPO on NYSE

08 Thg 05 2026
FDA Loosens Rules on Unauthorized Vapes Under Review